Centers | ||
|
|
|
EU-OPENSCREEN | Edinburgh Drug Discovery | FDA Oncology Center of Excellence Project Catalyst |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Providing a regulatory platform to connect scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation |
Partnerships |
Events |
Jobs |
Vanderbilt Enters Into Collaboration With BMS to Develop Drugs to treat Parkinsons DiseaseVanderbilt Center for Neuroscience Drug Discovery (VCNDD) and Bristol-Myers Squibb Company have entered into a broad collaboration agreement to co-develop new drugs to treat Parkinsons Disease. Under the collaboration agreement VCNDD will identify... View all Sanofi to Collaborate with UCSF to Develop New Drugs to Treat DiabetesUniversity of California, San Francisco (UCSF) has entered into a broad collaboration agreement with Sanofi to develop new therapies to treat Diabetes (Type 1 & 2). Scientists with deep biology expertise at Sanofi will be partnering with... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |
